NCT06928233 Association of TNFAIP3 With Immune-mediated TTP
| NCT ID | NCT06928233 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico |
| Condition | Thrombotic Thrombocytopenic Purpura, Acquired |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2025-04-07 |
| Primary Completion | 2026-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2025-04-07 with a primary completion date of 2026-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to investigate whether genetic variation in the TNFAIP3 locus is associated with immune-mediated thrombotic thrombocytopenic purpura (iTTP), and whether such association is mediated by decreased expression of A20 (TNFAIP3). The study includes a case-control design to assess genotype-expression association and a cohort study to evaluate clinical outcomes such as disease relapse.
Eligibility Criteria
Patients: Inclusion Criteria: * Diagnosis of iTTP * Above 12 years of age * Caucasian, Italian origin * Written informed consent to participate in the study Exclusion Criteria: * Patients who do not meet the above-listed criteria will be excluded from participation in the study. Controls will be healthy Italian volunteers of Caucasian ethnicity, with no history of thrombotic thrombocytopenic purpura, frequency-matched to cases by age and sex, and who have provided written informed consent to participate in the study.
Contact & Investigator
Ilaria Mancini, PhD
PRINCIPAL INVESTIGATOR
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Frequently Asked Questions
Who can join the NCT06928233 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, studying Thrombotic Thrombocytopenic Purpura, Acquired. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06928233 currently recruiting?
Yes, NCT06928233 is actively recruiting participants. Contact the research team at ilaria.mancini@guest.unimi.it for enrollment information.
Where is the NCT06928233 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06928233 clinical trial?
NCT06928233 is sponsored by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. The principal investigator is Ilaria Mancini, PhD at Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico. The trial plans to enroll 400 participants.